or Try an Advanced Search...

    Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 13.56 5.85% 0.75
    OLMA closed up 4.4 percent on Wednesday, September 18, 2024, on 1.5 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. It ran into resistance at its 50 day moving average.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical OLMA trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 5.85%
    200 DMA Support Bullish 5.85%
    Pocket Pivot Bullish Swing Setup 5.85%
    BB Squeeze Ended Range Expansion 5.85%
    Upper Bollinger Band Touch Strength 5.85%
    Crossed Above 200 DMA Bullish 10.51%
    Pocket Pivot Bullish Swing Setup 10.51%
    Bollinger Band Squeeze Range Contraction 10.51%
    Fell Below 200 DMA Bearish 10.97%
    Bollinger Band Squeeze Range Contraction 10.97%
    Older End-of-Day Signals for OLMA ...

       Recent Intraday Alerts

    Alert Time
    Possible Pocket Pivot about 1 hour ago
    1.5x Volume Pace about 7 hours ago
    Up 5% about 7 hours ago
    Up 1 ATR about 7 hours ago
    50 DMA Support about 7 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    OLMA Chart by TradingView
    Basic chart:

    Profile

    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant

    Is OLMA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 4 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Aug 21 Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
    Aug 6 Olema Pharmaceuticals GAAP EPS of -$0.54 beats by $0.01
    Aug 6 Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    Aug 1 Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
    Jun 17 Olema Pharmaceuticals: Still Merits A Small Holding
    Jun 14 TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors
    Jun 4 Pfizer data for breast cancer therapy sends Olema higher
    May 28 Olema Oncology to Participate in Upcoming Investor Conferences in June
    May 24 Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans
    See more OLMA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.7911
    52 Week Low 8.51
    Average Volume 605,734
    200-Day Moving Average 12.25
    50-Day Moving Average 13.02
    20-Day Moving Average 11.98
    10-Day Moving Average 12.27
    Average True Range 0.81
    RSI (14) 54.95
    ADX 18.6
    +DI 20.43
    -DI 12.26
    Chandelier Exit (Long, 3 ATRs) 10.63
    Chandelier Exit (Short, 3 ATRs) 13.33
    Upper Bollinger Bands 12.85
    Lower Bollinger Band 11.12
    Percent B (%b) 0.98
    BandWidth 14.50
    MACD Line -0.05
    MACD Signal Line -0.20
    MACD Histogram 0.1423
    Fundamentals Value
    Market Cap 705.79 Million
    Num Shares 55.1 Million
    EPS -2.31
    Price-to-Earnings (P/E) Ratio -5.55
    Price-to-Sales 0.00
    Price-to-Book 3.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 14.07
    Resistance 3 (R3) 14.01 13.53 13.86
    Resistance 2 (R2) 13.53 13.21 13.56 13.79
    Resistance 1 (R1) 13.17 13.01 13.35 13.23 13.72
    Pivot Point 12.69 12.69 12.78 12.72 12.69
    Support 1 (S1) 12.33 12.37 12.51 12.39 11.90
    Support 2 (S2) 11.85 12.17 11.88 11.83
    Support 3 (S3) 11.49 11.85 11.76
    Support 4 (S4) 11.55